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Histoplasma capsulatum is a dimorphic fungus of the As-
comycetes class. Histoplasmosis is the most common en-
demic mycosis in the USA and has emerged as an important
opportunistic infection among patients with HIV living in
or visiting endemic areas [1]. While the illness is subclini-
cal or presents as a mild self-limited pulmonary infection in
healthy individuals, the majority of cases involving AIDS
patients show signs of a life-threatening disseminated in-
fection. Presented here is a case of disseminated histo-
plasmosis in an HIV-infected patient living in Switzerland,
which was diagnosed by examination of a simple blood
smear.
A 45-year-old man was referred to our hospital in 2003
with a 3-week history of fever, cough, shortness of breath
and fatigue, a 3-month history of diarrhea (3–4 times a day),
and a 5-kg weight loss. The patient had been diagnosed
with HIV 5 years previously but had refused treatment.
Originally from Colombia, he had resided in Switzerland
since 1979. Three months before hospital admission, he
had visited his native country.
At the time of hospitalization, the patient was tachycardic
and tachypneic, with a temperature of 39.6◦C. Bilateral
pulmonary rales and hepatosplenomegaly were noted. The
abnormal laboratory findings were as follows: hemoglobin
7.9 g/dl, leukocyte count 9.9 G/l with left deviation of
36% and lymphopenia 6% (0.6 G/l), platelet count 17 G/l,
C-reactive protein level 221 mg/l, alanine aminotransferase
152 U/l, aspartate aminotransferase 301 U/l, and serum
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creatinine 1065 µmol/l. The CD4+ cell count was 16/mm3
and HIV RNA level 690,000 copies/ml. Chest radiograph
showed diffuse, nodular, interstitial infiltrates. Five days
after admission the patient developed bilateral pleural
effusions. Due to gastritis, a gastroscopy was performed,
revealing two pyloric ulcers.
The diagnosis of histoplasmosis was established by rou-
tine direct examination of a blood smear (Fig. 1a) and
blood staining with calcofluor. Fungi were also seen in
bronchoalveolar lavage (Fig. 1b), pleural liquid and bone
marrow, and cultures of these samples grew H. cap-
sulatum. Antimicrobial treatment was started with in-
travenous liposomal amphotericin B (250 mg/d for 13
days) and then switched to oral itraconazole (200 mg/d).
Due to the patient’s renal impairment, hemofiltration was
necessary during the first 3 days, and his anemia was
treated with transfusions of red blood cells. The pa-
tient also had several comorbid conditions, including cy-
tomegalovirus chorioretinitis, Kaposi’s sarcoma, oropha-
ryngeal candidiasis and giardiasis, for which he received
targeted treatment. His clinical evolution was slowly favor-
able, and he was transferred to a rehabilitation facility after
40 days.
At the time of transfer, the patient’s levels of serum cre-
atinine, transaminases and platelets had returned to nor-
mal, and his anemia had improved. Treatment consisted
of itraconazole, valganciclovir, 3TC, tenofovir and cotri-
moxazole. At 12-month follow-up, the patient’s CD4+ cell
count had risen to 145/mm3, and no relapse had occurred.
The decision was made to continue treating the patient with
itraconazole until his CD4+ cell count reached 200/mm3,
at which time treatment would be switched to highly active
antiretroviral treatment.
Although H. capsulatum has a worldwide distribution, it
is more prevalent in certain parts of North America, Central
and South America, Africa, and Asia [1]. Once regarded as
a rare disease, it is now the most common endemic mycosis
in the USA and one of the most common opportunistic
fungal infections in HIV-infected patients living in areas of
high prevalence [2], where it occurs in about 5% of AIDS
patients [3].
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Fig. 1 a Wright-Giemsa stain of peripheral blood smear. Numerous
circular inclusions with basophilic nuclei are visible in the cytoplasm
of neutrophils. A surrounding clear capsule is also visible. In addi-
tion, the neutrophils have large granules and vacuoles indicating a
severe infection. Elongated pale-blue Do¨hle bodies representing ac-
tive rough endoplasmic reticulum can also be seen in the neutrophils
on the left and at the bottom (enlargement 1000×). b Bronchoalveolar
lavage stain viewed with calcofluor under a fluorescence-microscope
Among cases of histoplasmosis occurring in Europe,
69 cases due to H. capsulatum and 17 cases due to H.
dubosii have been reported in the literature from 1980
to 1993, one-third of which occurred in AIDS patients
[1]. The first case of disseminated histoplasmosis in
Switzerland was diagnosed in 1984 in an HIV-infected
patient from Zaire [4]. In the subsequent Swiss HIV cohort
study, histoplasmosis accounted for 0.07% (11 cases) of
all AIDS-defining diseases identified between 1987 and
2002. All of these patients had resided in endemic areas.
In nearly all reports of histoplasmosis in patients with
AIDS, the infection has been disseminated [3, 5], while in
the general population only 1 in 2,000 individuals develops
disseminated infection [6]. An acute, rapidly fatal course
with diffuse reticuloendothelial involvement characterizes
the infection in these patients, and severity varies with
the degree of immune deficiency [1]. Patients often
present with shock, respiratory distress, hepatic and renal
failure, obtundation, and coagulopathy [5]. Respiratory
complaints, hepatosplenomegaly or lymphadenopathy are
present in one- to two-thirds of cases. Skin or mucosal
lesions are less frequent [5]. Although involvement of
the gastrointestinal tract is common, gastrointestinal
manifestations are relatively rare [7]. However, in certain
cases gastrointestinal and/or hepatic signs and symptoms
may predominate, and these patients may have no
pulmonary symptoms [8]. Symptoms of gastrointesti-
nal histoplasmosis can mimic other AIDS-associated
pathologies, making the diagnosis difficult. In some cases,
kidney lesions result from disseminated histoplasmosis,
as shown by renal biopsy [9]. Skin involvement was
found to be more common in a Brazilian than in a U.S.
cohort [10]. Disseminated histoplasmosis with a neuro-
logical focus could present with symptoms mimicking
cancer [11].
Recent guidelines for the treatment of disseminated histo-
plasmosis in patients with AIDS recommend a 12-week
induction therapy, initially starting with intravenous am-
photericin B deoxycholate, which can later be switched
to itraconazole to complete the 12-week course [12]. Fur-
ther investigation into the pathogenesis of disseminated
histoplasmosis at the molecular level is necessary in or-
der to identify new targets for the development of effective
therapy to eradicate the infection in immunocompromised
patients. For patients with AIDS, long-term maintenance
therapy with itraconazole is required after a severe mani-
festation of histoplasmosis to prevent relapses. Coadmin-
istration with lopinavir/ritonavir led to a strong increase in
itraconazole concentrations and its dosage must be adapted
when used in this combination.
Early diagnosis is crucial for the positive outcome of dis-
seminated histoplasmosis infection. Without treatment the
mortality rate is 80%; however, with early diagnosis and
antifungal therapy the mortality rate is usually <25% [11].
Therefore, it is important to recognize cutaneous histoplas-
mosis lesions so that prompt histologic evaluation and cul-
ture can be performed in suspected cases of disseminated
fungal infection, thereby expediting diagnosis and treat-
ment. Although immunocompromised patients may have
a large number of organisms in a lesion with a minimal
tissue reaction [8], serologic antigen tests for antibodies to
H. capsulatum are positive in about 80% of patients with
disseminated histoplasmosis [2].
In conclusion, histoplasmosis is a rare opportunistic
infection in Europe, but it must be included in the
differential diagnosis of opportunistic infections in
HIV-infected patients, mainly if they are returning from
endemic areas. Vigilance concerning the travel history of
patients must be maintained. Fungal staining of blood and
tissue samples, and even routine blood smear staining,
point toward the diagnosis of this infection, which
can be confirmed by the isolation of H. capsulatum in
culture.
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